Arvinas to present vepdegestrant data at breast cancer symposium

Arvinas Inc. (NASDAQ: ARVN) announced that five abstracts on its investigational drug vepdegestrant (ARV-471) have been accepted for presentation at the San Antonio Breast Cancer Symposium taking place December 9-12, 2025.

Vepdegestrant is an oral PROTAC estrogen receptor degrader being developed with Pfizer Inc. (NYSE: PFE) for estrogen receptor positive/human epidermal growth factor receptor 2 negative advanced or metastatic breast cancer with ESR1 mutations. The drug is under review by the FDA with a PDUFA action date of June 5, 2026.

The presentations will include subgroup analyses from the VERITAC-2 phase 3 trial, which compared vepdegestrant to fulvestrant in advanced breast cancer patients. Additional presentations will cover biomarker analyses from a phase 1/2 study, real-world prevalence data on ESR1 mutations, results from the I-SPY2 trial, and a combination study with PF-07248144.

Two presentations are scheduled as poster spotlight sessions on December 12, while three others will be standard poster presentations on December 10 and 12.

In the VERITAC-2 study, vepdegestrant demonstrated statistically significant improvement in progression-free survival compared to fulvestrant in patients with ESR1-mutated advanced breast cancer previously treated with endocrine-based therapy. The FDA has granted the drug Fast Track designation.

Arvinas and Pfizer announced a global collaboration for vepdegestrant development and commercialization in July 2021, sharing worldwide costs and profits. In September 2025, the companies announced plans to jointly select a third party for commercialization and potential further development of the drug.

You May Also Be Interested In

• ConectivGlobal launches ConeqtX and MyLife Wellness platforms
• Extra Space Storage prices $550 million senior notes offering at 4.900%
• Apollomics receives Nasdaq compliance notice, terminates license deal